Safety Evaluation of Nanoliposomes Containing Cyclosporine A After Ocular Administration
Authors:
- Touka BanaeeTBTouka Banaee
- Bizhan Malaekeh-NikoueiBMBizhan Malaekeh-Nikouei
- 11 May 2012
- journal article
- research article
- Published by Taylor & Francis in Current Eye Research
- Vol. 37 (6) , 453-456
Abstract
Aim: Cyclosporine A (CyA) is an anti inflammatory drug which modulates immune system. We prepared two liposomal formulations of CyA for ophthalmic administration. In the present study, the safety of these formulations was tested in rabbits. Materials and methods: Fusogenic and positively charged liposomes were prepared by solvent evaporation method. CyA concentration in ophthalmic preparations was 0.2% w/v. Twenty New Zealand albino rabbits (40 eyes) were divided into two groups. Right eyes were treated and left eyes served as control. Eyes were examined clinically in 1, 3, 7, 14 and 28th days of the study. Eleven eyes were enucleated for pathological evaluation at the end of the study. Results: Mean size and charge of positively charged and fusogenic liposomes were 110.7 ± 1.5 and 114.9 ± 15.2 nm; 19.0 ± 2.2 and 2.5 ± 0.5 mV, respectively. Clinically, there were transient conjunctival injections and corneal epithelial defects in a few cases which were not limited to the treated eyes. Positively charged liposomes caused conjunctival injection in two cases, while this complication occurred in only one eye after administration of fusogenic liposomes. Histopathological examination revealed the presence of follicular conjunctivitis in two eyes with conjunctival injection. Inflammation in cases received the fusogenic form of the drug was mild and non-specific. Conclusions: The results of this study suggest that fusogenic liposomal preparation of CyA is safe and can be useful for future studies.Keywords
This publication has 11 references indexed in Scilit:
- Corneal Graft RejectionInternational Ophthalmology Clinics, 2009
- The enhancement of immunosuppressive effects of cyclosporine A on human T-cells using fusogenic liposomesColloids and Surfaces B: Biointerfaces, 2008
- Immune modulation in corneal transplantationTransplantation Reviews, 2008
- Recent advances with liposomes as pharmaceutical carriersNature Reviews Drug Discovery, 2005
- Pharmacokinetic and Toxicity Study of an Intraocular Cyclosporine DDS in the Anterior Segment of Rabbit EyesInvestigative Ophthalmology & Visual Science, 2003
- Preparation and purification of cationic solid lipid nanospheres—effects on particle size, physical stability and cell toxicityInternational Journal of Pharmaceutics, 2003
- Prevention of topical and ocular oxidative stress by positively charged submicron emulsionBiomedicine & Pharmacotherapy, 1999
- The use of topical cyclosporin A in ocular graft-versus-host-diseaseBone Marrow Transplantation, 1998
- Major limitations in the use of cationic liposomes for DNA deliveryInternational Journal of Pharmaceutics, 1998
- Corneal graft rejection: a new rabbit model and cyclosporin-A.British Journal of Ophthalmology, 1982